Clearmind Medicine (CMND) Quarterly EPS earnings growth

Clearmind Medicine Inc. - graphic logo of issuer CMND

Clearmind Medicine Inc. (CMND) is actively advancing R&D for the MEAI molecule to combat alcoholism. The quarterly EPS growth rate demonstrates the company's development vector, where the 99.70 level represents the current value. Long-term factory quotas guarantee the stability of component supplies. Diversification through psychedelics for the therapy of eating disorders provides access to large-scale medical markets.

Clearmind Medicine Inc. (CMND) - Year-over-year earnings per one share growth for the last 12 months from 04/28/2023 to 11/18/2026

Analytical breakdowns and data insights for company clearmindmedicine.com (CMND)

- share price and consensus valuation forecast:
Fundamental valuation:Clearmind Medicine, Inc. - CMND
Flagship merchandise of Clearmind Medicine Inc.

This indicator measures the dynamics of quarterly net earnings per share, converted into a daily format to identify long-term trends in fundamental stability. By analyzing the current level of quarterly EPS growth, an investor can assess the impact of successful psychedelic clinical trials and the legal legalization of therapy on the capitalization of Clearmind Medicine Inc. (CMND), determining the real value of the business.

Analysis of competing companies

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|ATAI (atai.life) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research PLC (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (COMPASS Pathways PLC) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months lbpharma.us LBRX|Bright Minds Biosciences Inc (DRUG) - Earnings per share growth in annualized terms for the last twelve months|VNDA: Year-over-year net earnings per share growth for the last 12 months|Cybin Inc (CYBN) - Year-over-year net earnings per share growth for the last 12 months|Alto Neuroscience (ANRO) - Year-over-year earnings per share growth for the last twelve months|NRx Pharma - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cingulate|Year-over-year earnings per share growth for the last twelve months SILO|Year-over-year earnings per share growth for the last twelve months China Pharma (CPHI)|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth